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ABSTRACT
Human cells are constantly exposed to environ-
mental and endogenous agents which can induce
damage to DNA. Understanding the implications of
these DNA modifications in the etiology of human
diseases requires the examination about how
these DNA lesions block DNA replication and
induce mutations in cells. All previously reported
shuttle vector-based methods for investigating the
cytotoxic and mutagenic properties of DNA lesions
in cells have low-throughput, where plasmids con-
taining individual lesions are transfected into cells
one lesion at a time and the products from the rep-
lication of individual lesions are analyzed separately.
The advent of next-generation sequencing (NGS)
technology has facilitated investigators to design
scientific approaches that were previously not tech-
nically feasible or affordable. In this study, we de-
veloped a new method employing NGS, together
with shuttle vector technology, to have a multi-
plexed and quantitative assessment of how DNA
lesions perturb the efficiency and accuracy of DNA
replication in cells. By using this method, we
examined the replication of four carboxymethylated
DNA lesions and two oxidatively induced bulky DNA
lesions including (50S) diastereomers of 8,50-cyclo-
20-deoxyguanosine (cyclo-dG) and 8,50-cyclo-20-
deoxyadenosine (cyclo-dA) in five different strains
of Escherichia coli cells. We further validated the
results obtained from NGS using previously estab-
lished methods. Taken together, the newly de-
veloped method provided a high-throughput and
readily affordable method for assessing quantita-
tively how DNA lesions compromise the efficiency
and fidelity of DNA replication in cells.
INTRODUCTION
Human genome is constantly assaulted by endogenous
and exogenous agents (1), among which reactive oxygen
species (ROS) can be produced by normal aerobic metab-
olism, ionizing radiation and anti-tumoral agents (2).
Aside from single-nucleobase lesions, ROS could also
induce the formation of bulky DNA lesions including
8,50-cyclo-20-deoxyguanosine (cyclo-dG) and 8,50-cyclo-
20-deoxyadenosine (cyclo-dA) (3). In addition to ROS,
genomic DNA in living cells is susceptible to damage
from exposure to N-nitroso compounds (NOCs) in diet,
tobacco smoke and other environmental sources as well as
from endogenous sources (4). The exposure to endogenous
NOCs was found to be signiﬁcantly associated with the
risk of developing cancer (5). Some endogenously pro-
duced NOCs can be metabolized to give diazoacetate,
which induces the carboxymethylation of DNA (6,7).
The accumulation of ROS- and NOC-induced DNA
lesions may bear important implications in the pathogen-
esis of a number of human diseases including cancer and
neurodegeneration (5,8). However, the mutagenic
properties of these DNA lesions in cells remain unexplored.
Shuttle vector technology has been widely used for
examining how a structurally deﬁned DNA lesion affects
the efﬁciency and ﬁdelity of DNA replication in cells
(9,10). In this assay, a replicable plasmid harboring a
site-speciﬁcally inserted and structurally deﬁned lesion is
allowed to replicate in host cells. The progeny plasmids
are subsequently isolated and transfected into bacterial
cells for further ampliﬁcation and phenotypic selection.
Although this type of assay can couple with DNA
sequencing to determine the identities and frequencies of
mutations, phenotypic assay is indirect and potentially
affected by selection bias. It also necessitates scoring a
sufﬁcient number of mutations to obtain statistically
robust information. Recently, Delaney and Essigmann
(9,11) introduced the CRAB (competitive replication and
adduct bypass) and REAP (restriction endonuclease and
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and mutagenic properties of DNA lesions. In these assays,
the entire population of progeny genome is interrogated,
which affords statistically sound information about the by-
pass efﬁciencies and mutation frequencies, and no pheno-
typic selection is required. However, lesion-containing
M13 genomes are transfected into Escherichia coli cells
and analyzed one at a time, which is time-consuming.
The development of Sanger DNA sequencing method
about 30 years ago has had a profound impact on bio-
logical research, and the recent introduction of next-
generation sequencing (NGS) has made it feasible to pro-
duce a tremendous volume of sequencing data cheaply
(12). NGS technology has had a signiﬁcant impact on
genomic research (13,14) and had many applications
including whole-genome analysis of cancer cells (15),
genome-wide DNA cytosine methylation mapping (16),
DNA–protein interaction studies (ChIP-Seq) (17), etc.
NGS technology has enabled investigators to design sci-
entiﬁc approaches that were previously not technically
feasible or affordable. We reason that NGS technology
may render it possible to assess the mutagenic and cyto-
toxic properties of DNA lesions by sequencing a large
number of DNA molecules without tedious phenotypic
scoring. We also envision that, with the numerous reads
produced cheaply and rapidly by NGS and with a
bar-coding strategy, statistically sound results for the
bypass efﬁciencies and mutation frequencies of multiple
DNA lesions might be obtained from a single-sequencing
experiment.
In this study, we established an NGS coupled with shuttle
vector technology for high-throughput and cost-effective dis-
covery of how DNA lesions compromise DNA replication
in cells. Using this method, we assessed the mutagenic
and cytotoxic properties of four carboxymethylated
DNA lesions, N
4-carboxymethyl-20-deoxycytidine (N
4-
CMdC), N
6-carboxymethyl-20-deoxyadenosine (N
6-CMdA),
O
4-carboxymethylthymidine (O
4-CMdT) and N3-carboxy-
methylthymidine (N3-CMdT), and two oxidatively induced
bulky DNA lesions, (50S)-cyclo-dG and (50S)-cyclo-dA
(Figure 1).
MATERIALS AND METHODS
Chemicals and bacterial strains
Unmodiﬁed oligodeoxyribonucleotides (ODNs) used in
this study were purchased from Integrated DNA
Technologies (Coralville, IA, USA). [g-
32P]ATP was
obtained from Perkin Elmer (Piscataway, NJ, USA).
Shrimp alkaline phosphatase was obtained from USB
Corporation (Cleveland, OH, USA), and all other enzymes
were from New England Biolabs (Ipswich, MA, USA).
1,1,1,3,3,3-Hexaﬂuoro-2-propanol (HFIP) was purchased
from TCI America (Portland, OR, USA). Chemicals
unless otherwise noted were obtained from Sigma-
Aldrich (St Louis, MO, USA). M13mp7(L2) and wild-
type AB1157 E. coli strains were kindly provided by
Prof. John M. Essigmann, and polymerase-deﬁcient
AB1157 strains [pol B1::spec (pol II-deﬁcient), DdinB
(pol IV-deﬁcient), DumuC::kan (pol V-deﬁcient) and
DumuC::kan DdinB (pol IV, pol V-double knockout)]
were generously provided by Prof. Graham C. Walker (18).
Preparation of ODN substrates containing a modiﬁed
DNA lesion
The 12-mer lesion-containing ODNs 50-ATGGCGXGCT
AT-30 (‘X’ represents modiﬁed nucleoside) were synthe-
sized following previously published procedures (19–21).
The identities of the modiﬁed ODNs were conﬁrmed by
electrospray ionization-mass spectrometry (ESI-MS) and
tandem mass spectrometry (MS) analyses (Supplementary
Figures S1–S3). To differentiate the progeny vectors for
individual lesions after in vivo replication, a 10-mer ODN
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Figure 1. The structures of N
6-CMdC, N
6-CMdA, O
4-CMdT, N3-CMdT, (50S)-cyclo-dG and (50S)-cyclo-dA.
5946 Nucleic Acids Research, 2011,Vol.39, No. 14with a dinucleotide barcode (50-GCAGGATGBB-30, ‘BB’
represents barcode) was ligated to the 12-mer
lesion-bearing ODN and the resulting ligation product
was puriﬁed by denaturing PAGE (The 22-mer sequences
are listed in Table 1). The identities of the modiﬁed 22-mer
ODNs were again conﬁrmed by ESI-MS and tandem MS
analyses.
Construction of single-stranded M13 genomes harboring a
site-speciﬁcally inserted DNA lesion
The M13mp7(L2) viral genomes, either lesion-free or
carrying a site-speciﬁcally inserted DNA lesion, were pre-
pared following the previously described procedures (11).
Brieﬂy, 20pmol of single-stranded (ss) M13mp7(L2) was
digested with 40 U EcoRI at 23 C for 8h to linearize the
vector. Two scaffolds, 50-CATCCTGCCACTGAATCAT
GGTCATAGCTTTC-30 and 50-AAAACGACGGCCAG
TGAATTATAGC-30 (25pmol), each spanning one end of
the cleaved vector and the modiﬁed ODN insert, were
annealed with the linearized vector. The 22-mer insert
(30pmol, 50-GCAGGATGBBATGGCGXGCTAT-30,
where ‘X’ and ‘BB’ represent modiﬁed nucleoside and
the lesion-speciﬁc barcode, respectively) was
50-phosphorylated with T4 polynucleotide kinase. The
50-phosphorylated 22-mer inserts were ligated to the
above vector by using T4 DNA ligase in the presence of
the two scaffolds at 16 C for 8h. T4 DNA polymerase
(22.5 U) was subsequently added and the resulting
mixture was incubated at 37 C for 4h to degrade the scaf-
folds and residual unligated vector. The solution was ex-
tracted with phenol/chloroform/isoamyl alcohol (25:24:1,
v/v), and the aqueous phase was passed through the
QIAquick PCR Puriﬁcation column (Qiagen) to remove
residual phenol and salt. The constructed genomes were
normalized against a lesion-free competitor genome,
which was prepared by inserting a 25-mer unmodiﬁed
ODN (Table 1) into the EcoRI-linearized genome,
following the procedures described by Delaney and
Essigmann (11)
Transfection of E. coli cells with ssM13 vectors containing
a DNA lesion
Desalted N
4-CMdC-, N
6-CMdA-, O
4-CMdT-, N3-CMdT-,
(50S)-cyclo-dG- and (50S)-cyclo-dA-containing as well as
control M13 genomes were mixed at 1:1 ratio (25fmol
each) and transfected into SOS-induced wild-type
AB1157 E. coli cells and the isogenic E. coli cells that
are deﬁcient in pol II, pol IV, pol V, or both pol IV and
pol V. The electrocompetent SOS-induced cells were
prepared following the previously published procedures
(22). After transfection, the E. coli cells were grown in
LB culture at 37 C for 6h, after which the phage was
recovered from the supernatant by centrifugation at
13000r.p.m. for 5min. The resulting phage was further
ampliﬁed in SCS110 E. coli cells to increase the progeny/
lesion-genome ratio (11). The phage recovered from the
supernatant was passed through a QIAprep Spin M13
column (Qiagen) to isolate the ssM13 DNA.
Generation of sequencing library and determination of the
bypass efﬁciency and mutation frequency using NGS
The sequencing library was generated using NEBNext
DNA Sample Prep Master Mix Set 1 (New England
Biolabs, Ipswich, MA, USA; Figure 2). Brieﬂy, 15 sets
of primers each housing a unique dinucleotide barcode
(Supplementary Table S1), which designated host cell
lines or individual biological replicates, were employed
to generate polymerase chain reaction (PCR) products
from the progeny vectors. PCR ampliﬁcation of the
region of interest in the resulting progeny genome was
performed by using Phusion high-ﬁdelity DNA polymer-
ase (New England Biolabs) and running at 98 C for 60s
and 15 cycles at 98 C for 10s, 46 C for 30s and 72 C for
5s, with a ﬁnal extension at 72 C for 5min. The 15 sets of
PCR products were puriﬁed by QIAquick Nucleotide
Removal Kit (Qiagen) and then mixed at equal
amounts. The PCR mixture was phosphorylated at the
50-end using T4 polynucleotide kinase. A single ‘A’ nucleo-
tide was added to the 30 end of the PCR products and the
resulting puriﬁed PCR mixture was ligated to two paired-
end (PE) Adapters (Table S1). The ligation products were
further ampliﬁed using PE PCR primers (Supplementary
Table S1). The PCR ampliﬁcation was performed at 98 C
for 60s and 15 cycles at 98 C for 10s, 70 C for 30s and
72 C for 5s, with a ﬁnal extension at 72 C for 5min. The
resulting PCR products (166bp) were gel-puriﬁed and
subjected to NGS using Illumina Genome Analyzer IIe
system (Illumina, San Diego, CA, USA).
After obtaining the raw sequencing data, the reads that
failed to pass the Illumina chastity ﬁlter were removed.
The low-quality reads which contained >1nt with a
quality score below 20 or any undeﬁned nucleotide ‘N’
were further ﬁltered and removed. Only the reads with
perfect match to characteristic strings ‘ATTCAGTGGC
AGGATG’ from the 3rd–18th nucleotides and ‘ATGG’
from the 21st–24th nucleotides for forward sequence
reads, or the reads with perfect match to characteristic
strings ‘CGGCCAGTGAATTATAG’ from the 3rd–
19th nucleotides and ‘CCAT’ from the 24th–27th nucleo-
tides for reverse sequence reads were selected for analysis
of barcode distribution. An ‘R’ script was used to specify
cell line/biological replicate barcode or lesion-related
barcode at a given position, and to calculate the
nucleobase (A, T, C or G) frequencies at the speciﬁc
lesion site. The bypass efﬁciency was calculated using
Table 1. The sequences of the 22-mer lesion-containing and the
control lesion-free ODNs used for replication studies
Name of ODNs Sequences
N
4-CMdC 50-GCAGGATGCGATGGCGXGCTAT-30
N
6-CMdA 50-GCAGGATGATATGGCGXGCTAT-30
O
4-CMdT 50-GCAGGATGTCATGGCGXGCTAT-30
N3-CMdT 50-GCAGGATGTGATGGCGXGCTAT-30
Cyclo-dG 50-GCAGGATGGAATGGCGXGCTAT-30
Cyclo-dA 50-GCAGGATGAGATGGCGXGCTAT-30
Control 50-GCAGGATGACATGGCGCGCTAT-30
Competitor 50-GCAGGATGCGATGGCGATAAGCTAT-30
‘X’ in bold designates DNA lesion and the dinucleotide barcode is in
underlined bold font.
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Incorporate 
into plasmid
In-vivo 
replication
PCR 
amplification
PCR 
products
Add dA at 3’ end
Ligate to Illumina adaptors
PCR 
DNA lesion
Barcode for DNA lesion
DNA base after in-vivo repication
Sense PCR primer with barcode for different cell line
Antisense PCR primer with barcode for different cell line
PE Adapter 1 PE Adapter 2
PE PCR primer 1
Gel purification
Sequencing
PE PCR primer 2
PE DNA Sequencing primer 1
PCR 
products
5’-…CATGATTCAGTG GCAGGATGBBATGGCGXGCTAT AATTCACTGGCCGTCGTT…-3’
5’-…TGATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGTC…-3’
3’-BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB-5’
5’-BBATTCAGTG GCAGGATG-3’
3’-GATA TTAAGTGACCGGCBB-5’
5’-BBATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGBB-3’
In-vivo replication
5’-…CATGATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGTCGTT…-3’
PCR amplification with barcode-primers (15 cycles)
Resulting PCR products
Add 3’ dA, 5’-phosphorylation
Ligate to adapters
Gel purification
Sequencing
PCR amplification (15 cycles)
BBGCCGGTCACTTAA TATCGPGCGGTABBGTAGGACG GTGACTTABB
BBCGGCCAGTGAATT ATAGCQCGCCATBBCATCCTGC CACTGAATBB
BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB
BBGCCGGTCACTTAA TATCGPGCGGTABBGTAGGACG GTGACTTABB
27bp
29bp
BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB
BBATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGBB
BBGCCGGTCACTTAA TATCGPGCGGTABBGTAGGACG GTGACTTABB
BBCGGCCAGTGAATT ATAGCQCGCCATBBCATCCTGC CACTGAATBB
BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB
BBATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGBB
5’-…CATGATTCAGTG GCAGGATGBBATGGCGXGCTAT AATTCACTGGCCGTCGTT…-3’
5’-…TGATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGTC…-3’
3’-BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB-5’
5’-BBATTCAGTG GCAGGATG-3’
3’-GATA TTAAGTGACCGGCBB-5’
5’-BBATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGBB-3’
In-vivo replication
5’-…CATGATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGTCGTT…-3’
PCR amplification with barcode-primers (15 cycles)
Resulting PCR products
Add 3’ dA, 5’-phosphorylation
Ligate to adapters
Gel purification
Sequencing
PCR amplification (15 cycles)
BBGCCGGTCACTTAA TATCGPGCGGTABBGTAGGACG GTGACTTABB
BBCGGCCAGTGAATT ATAGCQCGCCATBBCATCCTGC CACTGAATBB
BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB
BBGCCGGTCACTTAA TATCGPGCGGTABBGTAGGACG GTGACTTABB
27bp
29bp
BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB
BBATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGBB
BBGCCGGTCACTTAA TATCGPGCGGTABBGTAGGACG GTGACTTABB
BBCGGCCAGTGAATT ATAGCQCGCCATBBCATCCTGC CACTGAATBB
BBTAAGTCAC CGTCCTACBBTACCGCQCGATA TTAAGTGACCGGCBB
BBATTCAGTG GCAGGATGBBATGGCGPGCTAT AATTCACTGGCCGBB
A
B
Figure 2. (A) A schematic diagram shows the experimental procedures. The 22-mer lesion-containing ODNs with barcodes were ligated to the EcoR
I-linearized M13 vector, mixed at equal amounts and subjected to in vivo replication. The harvested M13 progenies were ampliﬁed with barcoded
PCR primers, and equal amounts of PCR products from different cell lines were mixed and ligated with PE adapters. The ligation products were
further ampliﬁed using PE PCR primers, and the resulting PCR products were puriﬁed and subjected to NGS analysis. (B) Detailed sequence
information for the PCR ampliﬁcation of progeny genome, adapter ligation, and PCR ampliﬁcation for the construction of sequencing library. ‘X’,
‘P’ and ‘Q’ represent the lesion, the DNA base after in vivo replication of DNA lesion, and the paired nucleobase of ‘P’ in the complementary strand,
respectively. ‘BB’ in green and blue represent lesion-speciﬁc barcode and the barcode for host cell lines and biological replicates, respectively.
5948 Nucleic Acids Research, 2011,Vol.39, No. 14the following formula, %bypass=(total number of reads
from lesion genome) / (total number of reads from control
genome) 100%. The percentages of base substitution at
lesion site were calculated using the following formula,
%base substitution=(total number of reads of A, T, C
or G at original lesion site from lesion genome) / (total
number of reads from lesion genome) 100%.
Determination of bypass efﬁciency using CRAB assay
The bypass efﬁciencies of O
4-CMdT, (50S)-cyclo-dG and
(50S)-cyclo-dA were further evaluated by employing
CRAB assay developed by Delaney and Essigman (11)
The transfection and in vivo replication of
lesion-containing M13 vectors were conducted using pre-
viously described methods (11). PCR ampliﬁcation of the
region of interest in the resulting progeny genome was
performed by using Phusion high-ﬁdelity DNA polymer-
ase. The primers were 50-YCAGCTATGACCATGATTC
AGTGCCATG-30 and 50-YTCGGTGCGGGCCTCTTC
GCTATTAC-30 (Y is an amino group), and the ampliﬁ-
cation cycle was 30, each consisting of 10s at 98 C, 30s at
62 C and 15s at 72 C, with a ﬁnal extension at 72 C for
5min. The PCR products were puriﬁed by using
QIAquick PCR puriﬁcation kit (Qiagen).
For the bypass efﬁciency assay, a portion of the above
PCR fragments was treated with 10U Tsp509I in 10-ml
NEB buffer 2 at 65 C for 30min and 1U shrimp alkaline
phosphatase at 37 C for 30min, followed by heating at
65 C for 20min to deactivate the shrimp alkaline phos-
phatase. The above mixture was then treated in a 15-ml
NEB buffer 2 with 5mM DTT, ATP (50pmol cold,
premixed with 1.66pmol [g-
32P]ATP) and 10 U T4 poly-
nucleotide kinase. The reaction was continued at 37 C for
30min, followed by heating at 65 C for 20min to deacti-
vate the T4 polynucleotide kinase. To the reaction mixture
was subsequently added 10U BtsCI, and the solution was
incubated at 37 C for 30min, followed by quenching with
15-ml formamide gel loading buffer containing xylene
cyanol FF and bromophenol blue dyes. The mixture was
loaded onto a 30% native polyacrylamide gel (acryl-
amide:bis-acrylamide=19:1) and products were
quantiﬁed by phosphorimager analysis. After the restric-
tion cleavages, the original lesion site was housed in a
12-mer/18-mer duplex, d(pATGGCGPGCTAT)/ d(p*A
ATTATAGCQCGCCATBB), where ‘P’ represents the
nucleobase incorporated at the initial damage site during
in vivo DNA replication, ‘Q’ is the paired nucleobase of ‘P’
in the complementary strand, and ‘p*’ designates the
50-radiolabeled phosphate (Supplementary Figure S4).
The 18-mer products were monitored instead of the
12-mer products because the latter products co-migrated
with non-speciﬁc bands. The bypass efﬁciency was
calculated using the following formula, %bypass=(lesion
signal/competitor signal)/(non-lesion control signal/com-
petitor signal) (11). The mutation frequencies were
determined by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) since the 18-mers bearing a
single nucleobase difference could not be well-resolved
by PAGE.
Determination of bypass efﬁciency and mutation frequency
using LC-MS/MS
In order to identify the replication products using LC-MS/
MS, PCR products were treated with 50U BtsCI and 20U
shrimp alkaline phosphatase in 250-ml NEB buffer 2 at
37 C for 2h, followed by heating at 65 C for 20min. To
the resulting solution was added 50U of Tsp509I, and the
reaction mixture was incubated at 65 C for 1h followed
by extraction once with phenol/chloroform/isoamyl
alcohol (25:24:1, v/v). The aqueous portion was dried
with Speed-vac, desalted with high-performance liquid
chromatography (HPLC) and dissolved in 12-ml water.
The ODN mixture was subjected to LC-MS/MS
analysis. A 0.5 150mm Zorbax SB-C18 column (5mm
in particle size, Agilent Technologies) was used for the
separation and the ﬂow rate was 8.0ml/min, which was
delivered by using an Agilent 1100 capillary HPLC
pump. A 5-min gradient of 0–20% methanol followed
by a 35-min of 20–50% methanol in 400mM
1,1,1,3,3,3-HFIP, (pH was adjusted to 7.0 by the
addition of triethylamine) was employed for the separ-
ation. The efﬂuent from the LC column was coupled
directly to an LTQ linear ion trap mass spectrometer
(Thermo Electron, San Jose, CA, USA), which was set
up for monitoring the fragmentation of the [M-3H]
3-
ions of the 12-mer [d(ATGGCGPGCTAT), where ‘P’ des-
ignates A, T, C or G] and the [M-4H]
4- ion of the 15-mer
[i.e. d(ATGGCGATAAGCTAT)] ODNs.
RESULTS
Experimental strategy
Our strategy for high-throughput mutagenesis study
involves a combination of NGS with shuttle vector tech-
nology, as depicted in Figure 2. Following previously pub-
lished procedures (23–25), we constructed the ssM13
shuttle vectors carrying structurely deﬁned lesions at a
speciﬁc site and normalized the relative amounts of the
lesion-containing genomes. Six lesion-bearing and one
control M13 genomes were mixed together and transfected
simultaneously into E. coli cells. To illustrate the roles of
various translesion synthesis DNA polymerases in bypass-
ing these lesions in vivo, we employed wild-type AB1157 E.
coli cells as well as the isogenic strains deﬁcient in pol II,
pol IV, pol V or both pol IV and pol V as the host cells for
the replication experiments. After in vivo replication, the
ssM13 progeny vectors were isolated. Fifteen pairs of
barcoded primers (Supplementary Table S1), which
designated 15 distinct sets of progeny genomes arising
from triplicate replication experiments in ﬁve different
host cell lines, were employed to generate PCR products
from the progeny vectors. The 15 sets of PCR products
were then mixed at equal amounts and the resulting PCR
product mixture was phosphorylated at the 50-end,
adenylated at the 30-end, and ligated to PE adapters 1
and 2 (Supplementary Table S1). The ligation products
were further ampliﬁed using PE PCR primers
(Supplementary Table S1), and the resulting PCR
products (166bp) were gel-puriﬁed and subjected to
Nucleic Acids Research, 2011,Vol.39, No. 14 5949NGS analysis using Illumina Genome Analyzer IIe
system. From the sequencing results, we determined the
mutagenic and cytotoxic properties of multiple DNA
lesions in different bacterial hosts by interrogating the dis-
tribution of barcodes and nucleobase (A, T, C or G)
frequencies at the speciﬁc lesion site. In addition, the
sequencing reads obtained for the lesion-containing
genomes relative to the lesion-free genome allowed for
the calculation of bypass efﬁciencies for the lesions.
Synthesis of lesion-containing ODNs
Previous studies demonstrated that potassium diazoace-
tate was capable of inducing N
4-CMdC, N
6-CMdA, O
4-
CMdT and N3-CMdT in isolated DNA (20,21). In
addition, ROS-induced bulky DNA lesions including
cyclo-dG and cyclo-dA could be detected in mammalian
cells (26–28) (Figure 1), though a recent study suggested
that the cellular levels of cyclo-dG and cyclo-dA might be
lower than those measured previously (29). However, it
remains unexplored how these lesions compromise the
ﬁdelity and efﬁciency of DNA replication in vivo. Such
studies necessitate the availability of ODNs containing
site-speciﬁcally incorporated DNA lesions. To this end,
we employed traditional phosphoramidite chemistry and
synthesized N
4-CMdC-, N
6-CMdA-, O
4-CMdT-,
N3-CMdT-, cyclo-dG- and cyclo-dA-containing ODNs,
50-ATGGCGXGCTAT-30 (‘X’ represents modiﬁed nu-
cleoside) (19–21). After HPLC puriﬁcation, the purities
and identities of these lesion-bearing ODNs were con-
ﬁrmed by ESI-MS and tandem MS (MS/MS) analyses
(Figures S1–S3). The lesion-bearing 12-mer ODNs were
then ligated with barcode-containing 10-mer ODNs to
yield the 22-mer lesion-containing ODNs (Table 1).
NGS analysis of the bypass efﬁciencies and mutation
frequencies of DNA lesions
In this study, we mixed six lesion-containing M13
genomes and a control lesion-free M13 genome and
allowed them to replicate in ﬁve different E. coli strains.
We obtained a total of 9.6 million valid sequencing reads
for the replication products of these genomes and
Supplementary Table S2 shows the typical number
of reads obtained for replication products isolated from
wild-type E. coli cells. Even with the most blocking DNA
lesion, i.e. (50S)-cyclo-dG, we still obtained about 10000
reads in a single replicate experiment (Supplementary
Table S2), which is much more than what can be
achieved with traditional colony picking and Sanger
sequencing method.
The bypass efﬁciencies were calculated from the ratio of
the total number of reads from lesion genome over the
total number of reads from the control genome. It
turned out that N
4-CMdC and N
6-CMdA did not block
DNA replication in wild-type AB1157 E. coli cells, with
the bypass efﬁciencies being  83% and 98%, respectively
(Figure 3A). In addition, deﬁciency in pol II, pol IV or pol
V in the isogenic AB1157 background did not affect con-
siderably the bypass efﬁciencies for these two lesions
(Figure 3A). O
4-CMdT and N3-CMdT, on the other
hand, block appreciably DNA replication in wild-type
AB1157 E. coli cells, with the bypass efﬁciencies being
 49% and 55%, respectively (Figure 3A). Deﬁciency in
pol II, pol IV or pol V in the isogenic AB1157 background
did not compromise the bypass efﬁciency for N3-CMdT
(Figure 3A). Although deﬁciency in pol II or pol IV in the
isogenic AB1157 background did not alter substantially
the bypass efﬁciencies of O
4-CMdT, deﬁciency in pol V
alone or in combination with pol IV decreased the bypass
efﬁciencies to 22% and 19%, respectively, indicating
that pol V may be involved in the bypass of O
4-CMdT
(Figure 3A).
Cyclo-dG and cyclo-dA inhibited substantially the
DNA replication in wild-type AB1157 cells, with the
bypass efﬁciencies being  11% and 31%, respectively
(Figure 3B). Deﬁciency in pol II or pol IV did not affect
considerably the bypass efﬁciencies for these two lesions;
however, depletion of pol V alone or in conjunction with
pol IV gave rise to further declines in bypass efﬁciencies of
cyclo-dG to 6% and 4%, respectively. Likewise, the
bypass efﬁciencies of cyclo-dA dropped to 13% and
10% in pol V-deﬁcient and pol IV, pol V-double knockout
cells, respectively. These data supported that pol V is the
major DNA polymerase involved in the bypass of
cyclo-dG and cyclo-dA in E. coli cells (Figure 3B).
The results from NGS data also allowed us to assess the
mutation frequencies of DNA lesions in wild-type and
bypass polymerase-deﬁcient E. coli strains. The quantiﬁ-
cation data showed that: (i) Neither N
4-CMdC nor
N
6-CMdA was mutagenic; (ii) both O
4-CMdT and
N3-CMdT were highly mutagenic in wild-type E. coli
cells, with T!C transition and T!A transversion
occurring at frequencies of 86% and 66%, respectively;
(iii) cyclo-dG and cyclo-dA were mutagenic in wild-type
E. coli cells, with the major types of mutations being
G!A transition and A!T transversion at frequencies
of 20% and 11%, respectively. The deﬁciency in
SOS-induced polymerases did not confer signiﬁcant alter-
ation in the mutation frequencies of all these DNA lesions
except for N3-CMdT, where the deﬁciency in pol V, by
itself or along with pol IV, resulted in signiﬁcant increases
in T!A mutation (Figure 3C–H).
It is worth noting that deﬁciency in pol V led to a
decreased bypass efﬁciency, but did not give rise to an
appreciable change in mutation frequency of O
4-CMdT.
A lack of alteration in mutation frequency was also
observed previously for other DNA lesions including
S
6-methythioguanine and guanine-S
6-sulfonic acid in pol
V-deﬁcient background, whereas decreased bypass
efﬁciencies were found for both lesions in pol V-deﬁcient
cells (24). The exact reason behind these observations is
unclear, though it is possible that the coding property of
O
4-CMdT might be interpreted similarly by pol V in the
wild-type background and other polymerase(s) that are
involved in bypassing this lesion in the pol V-deﬁcient
background.
We also found an appreciable drop in T!A mutation
for N3-CMdT in pol IV-deﬁcient cells, whereas the bypass
efﬁciency was not perturbed by the deﬁciency in this poly-
merase. This result suggests that pol IV might be involved
in the mutagenic bypass of this lesion in wild-type back-
ground. A very similar ﬁnding was made by a previous
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Figure 3. (A) Bypass efEciencies of N
4-CMdC, N
6-CMdA, O
4-CMdT and N3-CMdT. (B) Bypass efEciencies of (50S)-cyclo-dG and (50S)-cyclo-dA.
(C–H) Mutation frequencies of N
4-CMdC, N
6-CMdA, O
4-CMdT, N3-CMdT, (50S)-cyclo-dG and (50S)-cyclo-dA. The data represent the means and
standard deviations of results from three independent experiments.
Nucleic Acids Research, 2011,Vol.39, No. 14 5951elegant study by Neeley et al. (22), where the mutation
spectra of 5-guanidino-4-nitroimidazole (NI) were
observed to be signiﬁcantly different in SOS-induced
wild-type strain versus the corresponding pol II-deﬁcient
strain; however, the bypass efﬁciencies for this lesion were
very similar in these two strains. The exact reason behind
our observation is unclear, though we speculate that other
polymerase(s) might be induced at a higher level in pol
IV-deﬁcient background than in the wild-type back-
ground, which may compensate for the decrease in
bypass efﬁciency induced by the absence of pol IV.
Next, we compared the bypass efﬁciencies of O
4-CMdT,
cyclo-dG and cyclo-dA under uninduced and SOS-
induced conditions in wild-type AB1157 cells by using
CRAB assay (Supplementary Figure S4). Compared to
uninduced conditions, the quantitative results showed
that the bypass efﬁciencies of O
4-CMdT, cyclo-dG and
cyclo-dA in SOS-induced cells increased from 10% to
52%, 3% to 14%, 5% to 29%, respectively, which are
corroborated by results obtained from LC-MS/MS meas-
urements (Figure 4A and Supplementary Figure S4C).
The 4- to 6-fold elevation in bypass efﬁciencies for these
lesions in SOS-induced cells supported that higher level of
expression of SOS-induced polymerases stimulated the
bypass of these lesions. In addition, the mutation rates
and patterns of O
4-CMdT and cyclo-dA are similar in
uninduced and SOS-induced wild-type cells. However,
the G!A mutation induced by cyclo-dG decreased
from  40% in uninduced cells to  20% in SOS-induced
cells.
Determination of bypass efﬁciencies using CRAB assay
To conﬁrm the results obtained by NGS, we further
examined the bypass efﬁciencies of O
4-CMdT, cyclo-dG
and cyclo-dA by employing CRAB assay (Supplementary
Figure S4). It turned out that the bypass efﬁciencies of
O
4-CMdT, cyclo-dG and cyclo-dA in wild-type AB1157
E. coli cells, obtained using CRAB assay, were  52%,
14% and 29%, respectively, which were very similar to
those obtained from NGS analysis (49%, 11% and
31%, respectively; Figure 4A).
Determination of bypass efﬁciencies and mutation
frequencies using LC-MS/MS
We also validated the bypass efﬁciencies and mutation
frequencies obtained from NGS using our previously
reported LC-MS/MS method (23–25). In this respect,
the restriction digestion mixture was analyzed by
LC-MS/MS and we monitored the fragmentation of the
[M   3H]
3  ions of d(ATGGCGPGCTAT), where ‘P’ is
an A, T, C or G, and the [M   4H]
4  ion of d(ATGGCG
ATAAGCTAT) (Supplementary Figures S5 and S6). We
then quantiﬁed the mutation frequencies and bypass
efﬁciencies based on the relative amounts of different rep-
lication products with the consideration of differences in
ionization and fragmentation efﬁciencies for different
ODNs [LC-MS/MS data are shown in Figures S5 and
S6, and calibration curves are depicted in Supplementary
Figure S7]. It turned out that the bypass efﬁciencies and
mutation frequencies for O
4-CMdT, cyclo-dG and
cyclo-dA were consistent with what we found from NGS
analysis (Figure 4).
DISCUSSION
NGS technology has found its applications in many
aspects of biological research; however, it has not been
employed for assessing how DNA lesions compromise
DNA replication in cells. In the current study, we de-
veloped, for the ﬁrst time, a high-throughput and
cost-effective method by employing NGS in conjunction
with shuttle vector technology for examining how
carboxymethylated DNA adducts and ROS-induced
bulky DNA lesions impede the progression of DNA rep-
lication and induce mutations in E. coli cells.
With this method, we demonstrated that N
4-CMdC and
N
6-CMdA did not block DNA replication or induce mu-
tations in E. coli cells (Figure 3). Our previous primer
extension experiments showed that N
4-CMdC, but not
N
6-CMdA, inhibited markedly primer extension
mediated by the Klenow fragment of E. coli DNA poly-
merase I (20). Klenow fragment incorporated readily the
wrong nucleotide, dAMP, opposite N
6-CMdA, and the
enzyme also induced the misinsertion of dAMP and
dTMP opposite N
4-CMdC (20). Several factors may
contribute to the observed differences in nucleotide
incorporation opposite N
4-CMdC and N
6-CMdA with
Klenow fragment and in E. coli cells. First, DNA
replication in E. coli cells may require both pol I and
pol III (30). Second, the in vitro measurements were
carried out in the presence of one kind of nucleotide at
a time, which is different from in vivo replication condi-
tions where all four nucleotides are mutually present.
Third, in vivo DNA replication often involves the partici-
pation of auxiliary protein factors, which can alter both
the efﬁciency and accuracy of nucleotide insertion by
DNA polymerases (31).
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Figure 4. (A) Bypass efEciencies of O
4-CMdT, (50S)-cyclo-dG and
(50S)-cyclo-dA measured by three different methods, NGS, CRAB
assay and LC-MS/MS. (B–D) Mutation frequencies of O
4-CMdT,
cyclo-dG and cyclo-dA measured by NGS and LC-MS/MS. The data
represent the means and standard deviations of results from three in-
dependent experiments.
5952 Nucleic Acids Research, 2011,Vol.39, No. 14The bypass efﬁciencies for O
4-CMdT and N3-CMdT in
wild-type AB1157 E. coli cells are  49% and 55%, re-
spectively. Both O
4-CMdT and N3-CMdT are highly mu-
tagenic in wild-type AB1157 cells, with the major types of
mutations being T!C transition and T!A transversion
at frequencies of 86% and 66%, respectively (Figure 3).
Previous studies revealed that diazoacetate could lead to
the formation of O
4-CMdT and N3-CMdT in isolated
DNA (21). In addition, the passage of diazoacetate-
treated, human p53 gene-containing plasmid in yeast
cells could give rise to a mutation spectrum where the
types and frequencies of mutations observed at
non-CpG sites were strikingly similar to those found for
p53 gene mutations in human gastrointestinal tumors (32).
This result suggests that diazoacetate might constitute an
important etiological agent for gastrointestinal cancer de-
velopment. In addition,  43% of all mutations occurred
at AT base pairs, with AT!TA, AT!GC and
AT!CG substitutions occurring at frequencies of 20%,
12%, 10%, respectively (32). The high frequencies of
T!C and T!A mutations found for O
4-CMdT and
N3-CMdT suggest that these lesions may contribute to
p53 mutations induced by diazoacetate and found in
human gastrointestinal tumors.
Our NGS data also revealed that (50S)-cyclo-dG and
(50S)-cyclo-dA blocked strongly the DNA replication in
E. coli cells, which is in line with previous studies
showing that cyclo-dA is a strong blockade to T7 DNA
polymerase and mammalian DNA polymerase d in vitro
(33), and to RNA polymerase II in mammalian cells (34).
Additionally, cyclo-dG and cyclo-dA were mutagenic in
E. coli cells, with the major types of mutations being
G!A transition and A!T transversion at frequencies
of 20% and 11%, respectively. Cyclo-dG and cyclo-dA, in
which C8 of a purine base is covalently bonded to the C50
of 2-deoxyribose in the same nucleoside, are formed from
hydroxyl radical attack (33,35). Because of the presence of
a covalent bond between 2-deoxyribose and purine
moieties, these lesions are not repaired by base excision
repair system but by the nucleotide excision repair
pathway (33,34). This additional covalent bond causes
local structural distortion to the DNA helix (33), which
may compromise the base pairing capabilities of these
DNA lesions thereby inducing mutations during DNA
replication in vivo. It is worth noting that we attempted
but failed to ﬁnd deletion or off-target mutation for (50S)-
cyclo-dG and (50S)-cyclo-dA. Considering that cyclo-dG
and cyclo-dA can be detected in mammalian cells (26–28),
the cytotoxic and mutagenic properties of cyclo-dG and
cyclo-dA suggest that the formation and accumulation of
these lesions in vivo may bear signiﬁcant pathological
consequences.
Introducing barcodes into M13 genome allowed for the
high-throughput evaluation of the cytotoxic and mutagen-
ic properties of DNA lesions. In the present study, di-
nucleotide barcodes were used to represent different
DNA lesions and cell line hosts, and the replication of
up to 16 different lesion-containing genomes in up to 16
different cell lines can be analyzed simultaneously.
Expanding the length of the barcode sequence can
further increase the numbers of lesions investigated and
the number of host cells studied, thereby improving
further the throughput of the method. On the Illumina
platform, the single-end read-lengths are typically up to
40bp; longer reads are possible but may incur a higher
error rate. In our case, a valid read should include a cell
line barcode, the lesion barcode and the lesion site. In this
regard, 27bp of forward sequence and 29bp of reverse
sequence (Figure 2B), which were fully covered in the
40-bp sequencing range, satisﬁed the requirement for a
valid read.
Lastly, it is worth noting that we only assessed the mu-
tagenic and cytotoxic properties of the six DNA lesions in
a single-sequence context, and it is possible that the bypass
efﬁciencies and mutation frequencies of DNA lesions may
differ in different sequence contexts. The NGS-based
method developed in the present study can be applicable
for assessing the effects of sequence context on DNA rep-
lication in the future. Similar as traditional CRAB assay
(9), the NGS method reported here can also be employed
for investigating how DNA lesions are repaired in cells.
Additionally, with the use of a double-stranded vector, the
method can be adapted for examining the cytotoxic and
mutagenic properties of DNA lesions in mammalian cells
(36). Taken together, our current study demonstrated that
NGS, combined with shuttle vector technology, provided
a high-throughput and cost-effective method to un-
cover the cytotoxic and mutagenic properties of DNA
lesions.
It is worth noting that the method reported in this study
also bears some limitations, which arises primarily from
the error rate introduced by the NGS method. In this
context, we observed an error rate of 1.2% for the
control genome (Supplementary Table S2), which is
higher than the error rate obtained by the Sanger
sequencing method and slightly higher than the average
sequencing error rate on the Illumina platform (37). The
latter could be attributed, in part, to the sequencing error
produced at the barcode sites. Considering the error rate
of 1.2%, a lesion with an induced mutation frequency that
is >3–4% could not be investigated with the strategy
described in this paper. Nevertheless, future improvements
in sequencing accuracy of NGS, which has been continu-
ously improving since its inception, and the use of longer
barcode sequence are expected to improve the accuracy in
determining the mutation frequency.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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